Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: Westerner who wrote (809)	4/18/1998 12:07:00 PM
From: dfloydr	Read Replies (2) \| Respond to of 1055

Interesting! I had heard that they had trouble with their plan to be the first initial public offering on that exchange and yet they managed to move forward. I also heard that they likely faced improbable odds of getting approved for sale in Europe in a timely way. So if they are funded by Bard and Bard is to sell their output here, their two major hurdles are gone. This stuff has a very short half life, so add a day of deterioration for transatlantic shipment and calculate accordingly. Sounds - to an amateur - as though it should work. It still leaves open the fact that the THRX cyclotrons apparently contain propriatary art, if not actual patents, that THRX has enjoined the Belgian cyclotron maker from passing on to others. I think that happened about fifteen months ago. From past experience in Africa, enjoining a Belgian business will have no useful effect, but US courts could see things differently and that could tie up sale of their output here. Floyd